Prof Sandra Swain speaks to ecancer at BGICC 2023 about the management of HER2 positive metastatic breast cancer treatment algorithm.

She highlights that a number of significant advances have been made in this area over the past few decades.

Prof Swain also outlines the key findings of one of her previous studies, CLEOPATRA, which showed a 37% survival at 8 years for HER2 positive metastatic breast cancer patients.